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Abstract. HIV infection, if left untreated, leads in most cases to the development of wide immune deterioration, opportunistic
infections and eventually AIDS and death. The identification of individuals who despite persisting infection show no or few
signs of HIV disease progression has spurred hopes that an effective HIV vaccine could be attainable. The design of such a
vaccine will greatly depend on the precise definition of disease markers, host genetic and immune characteristics that mediate
relative in vivo control of this virus. Accordingly, a number of viral factors and host genetic characteristics have been shown to
play a crucial role in the control of HIV disease by delaying progression to AIDS or even preventing infection. There is also an
improved understanding of humoral and cellular immune responses in terms of specificity, functional repertoire, longevity and
tissue distribution and their ability to contain HIV replication. However, the definition of good immune correlates unequivocally
and causally associated with protection or disease progression remains elusive. Here we review work on viral factors, host genetic
markers and immunological determinants that have been identified in individuals with superior control of HIV infection or in
subjects who remain uninfected despite frequent exposure to the viral pathogen.
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1. Introduction
The AIDS pandemic is one of the greatest global
health crises of our time. Since HIV was identified 25
years ago, 23 million people have died and 33 million
more are living with HIV [1]. Despite advances in edu-
cation, HIV prevention and improvements in access to
antiretroviral drugs, the pandemic continues to outpace
global efforts at prevention and control. According
to the United Nations Development Program (UNDP),
HIV has inflicted the “single greatest reversal in human
development” in modern history [2].
AIDS vaccine research and development is of highest
priority today and, at the same time, one of the biggest
scientific challenges the immunology field faces. The
enormous viral variability together with human host
genetic diversity throughout the world are primary fac-
tors hampering the development of efficient strategies
to control and prevent HIV infection and the design of
potentially effective immune-based therapeutic inter-
ventions and prophylactic vaccines. The recent failure
in 2007 of a phase III trial of a prophylactic vaccine
candidate further highlighted how far the field is still
away from reliable markers of HIV control and how to
best design an effective vaccine. Thus, an improved
understanding of the immunopathogenesis of HIV in-
fection and the role of host genetic markers and viral
diversity in this control is urgently needed. However,
it will likely not be sufficient to link certain more or
less random markers with clinically well-established
parameters of disease progression, such as plasma viral
RNA levels and nadir CD4+ T-cell counts or CD4+
T-cell counts decline over time. Rather, specific mark-
ers that are directly mediating viral control need to be
identified so that vaccine design is not misled by focus-
ing on epiphenomena and functionally unlinked mark-
ers. This is certainly easier said than done as determi-
nants of an effective viral control will likely need to
be identified in multifactorial models that incorporate
viral variability, environmental particularities (such as
co-infections) and host genetics.
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Here we review the role of viral factors, host genet-
ics markers and HIV specific immune responses in the
control of HIV infection and their possibly underlying
mechanisms. The determinants of viral attenuation,
specific HLA class I and II alleles, certain polymor-
phisms in co-receptor genes and ligands, the specificity
and functionality of virus-specific CD4+ and CD8+
T-cell responses, as well as new insights into factors of
the innate immune response in HIV control are being
discussed.
2. Insights from studies in individuals with
self-controlled viral replication and HEPS
cohorts
Infection with HIV leads to a devastating erosion of
the immune system clinically characterized by a pro-
gressive rise in HIV viral load and decrease of the num-
ber of CD4+ T-cells. This decline in CD4+ T-cells
heralds the progression to AIDS with its associated op-
portunistic infections and cancers and ultimately ends
in death.
Among the HIV-infected population, several groups
of individuals have been identified that remain clini-
cally stable and free of any AIDS defining conditions
for decades after infection in the absence of antiretro-
viral therapy [3]. These individuals (estimated to be 5–
8% out of the total HIV-infected population) have been
referred to as long term survivors (LTS) or long-term
non-progressors (LTNP) and are generally able to con-
trol viral replication to low levels – plasma RNA levels
< 2,000 copies/ml (or < 5,000-10,000 copies/ml, de-
pending on arbitrary cut-offs decided upon by differ-
ent investigators) and to maintain normal CD4+ T-cell
counts over time with a reduced rate of CD4+ T-cell
loss (18 cells/µl/year) compared to that in normal pro-
gressors (around 60 cells/µl/year) [4]. A subset of such
LTNP is able to maintain undetectable plasma viral
loads for extensive period of times and is known as elite
controllers (EC). The clinical and scientific interest in
such individuals is great as they may indeed hold the
key of spontaneous control of HIV infection. Current
efforts have allowed for the establishment of large inter-
national cohorts of controllers and elite-controllers and
an intensive search for host genetic, virological as well
as immunological markers of HIV control is ongoing
in these subjects.
Some recent work on elite controllers (estimated to
represent less than 1% of the HIV infected population)
has shown wide heterogeneity in the immunological
and clinical course of HIV infection despite certain
similarities in genetic determinants [5], again suggest-
ing that HIV control needs to be seen in a context that
integrates host genetics, immune function as well as
virological diversity. Nevertheless, these and earlier
analyses have directly allowed to identify a number of
properties of the immune response to HIV (specifici-
ty, T cell polyfunctionality), as well as host genetic
markers (mainly HLA class I alleles) that are strongly
associated with disease control and which will prove
helpful in the quest of developing a broadly applicable
HIV vaccine.
Similarly, highly Exposed Persistently Seronegatives
(HEPS) individuals, such as some commercial sex
workers or discordant couples who are multiply ex-
posed to HIV yet remain uninfected, may also provide
important clues into potential mechanisms of HIV con-
trol and even prevention of infection [6,7]. However,
these studies need to always be well documented for
real exposure to HIV, even more so now that studies in
discordant couples sometimes include HAART treated
subjects which put the seronegative partner at clearly
reduced risk of HIV acquisition. Some recent stud-
ies have identified genetic polymorphisms in the SDF1
gene, specific CD8+ T cell responses and IgA produc-
tion as factors associated with a reduced risk of HIV
acquisition in these groups [8–12]. However, T cell re-
sponse rates and antibody production have not emerged
consistently in all studies as potentially protective [13,
14] and further studies are needed to clarify these find-
ings. In addition, immune analyses conducted to iden-
tify potentially protective immune responses need to be
based on sensitive but specific assays and stringent cut-
offs [15]. Given these considerations, it can reasonably
be expected that future analyses on HEPS may provide
further valuable information.
3. Viral determinants in control of HIV-infection
While individuals with apparently effective con-
trol of HIV infection (LTNP, elite controllers) have
been studied exhaustively for virus-specific immune re-
sponses, less is known about potential virological de-
terminants that could be driving the observed control.
A number of studies have identified single individuals
or small cohorts (such as the Sydney Blood Bank Co-
hort –SBBC- a unique collection of individuals infected
with an attenuated HIV-1 virus from a common donor)
that harbor partially defective viruses that seem to have
a decreased replication competency. Others have also
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been able to isolate virus with impaired replicative ca-
pacity from PBMC cultures generated from LTNP, sup-
porting the hypothesis that primary infection by ‘atten-
uated virus strains’ with slow replication kinetics may
facilitate control of viremia [16]. This is not only of
relevance to the replication fitness of potentially part-
ly defective viruses as it could also reduce the kinet-
ics of viral evolution and CD4+ T cell depletion over
prolonged period of time.
A certain ‘acquired’ degree of attenuation in terms
of impaired replicative capacity could be partially in-
duced by antiretroviral therapy,as individuals who were
efficiently treated for long periods of time showed a
prolonged delay in restoration of pretreatment viral di-
versity after therapy interruption (STI). This suggested
that punctuated antiretroviral therapy may cause a con-
siderable evolutionary bottleneck leading to the emer-
gence of viral populations with overall reduced viral fit-
ness [17]. However, it could also reflect improved im-
mune competence and at least partial immune restora-
tion after prolonged treatment periods, which could on
its own impact viral repopulation dynamics.
Aside from treatment-induced viral variants, sever-
al viral genetic defects and polymorphisms that impair
replicative capacity have been implicated in mediating
relative viral control. Viral genomes carrying deletions
or inactivating variants in the nef gene or in the over-
lap of nef and the U3 region of the long terminal re-
peat (LTR) were among the very first viral defects as-
sociated with control. These cases were identified in
1995 in a group of 6 individuals from the SBBC cohort
who had become infected after obtaining blood trans-
fusions from the same HIV-infected blood donor but
remained free of HIV-related disease [18]. Although
still unclear, one potential underlying mechanism sug-
gested for the beneficial effects of this nef deletion is
that Nef is no longer available to down-regulate HLA
class I molecules and infected cells thus would be more
readily recognized by HIV-specific CD8+ T cells [19].
However, longitudinal analysis of viral evolution of
the nef/LTR sequences over time in the SBBC cohort,
were unable to fully explain mechanisms that could
have contributed to slow progression of HIV disease in
2 (out of the 6) individuals of the cohort, suggesting
that nef gene deletions are not necessarily mediating
life-long protection from disease progression. Thus,
other viral and/or host factors plus immune pressure
was likely contributing to the long-term control in these
individuals [20].
Aside from Nef-mediated effects, other mutations
in structural proteins have been associated with slower
disease progression as well. These include unusual,
difficult-to-revert polymorphisms and 1–2 amino acids
deletion in gp41 and Gag or a four amino acids insertion
in Vpu among others [21]. In addition, replication de-
fective strains have been identified when constructing
viral clones with mutations at the rev activation domain,
which were seen more frequently in controller individ-
uals than in subjects with regular HIV disease progres-
sion [22]. In addition, to these mutations of unknown
origin in terms of specific selective force (apart from
reduced replication capacity), viral mutations evolv-
ing under strong immune selection pressure have been
show to lead to reduced viral replication (see below).
Despite these reported cases of reduced replicative
viruses and slower disease progression, the frequency
and contribution of such defects on the maintenance of
undetectable viremia is not well established. In partic-
ular, conflicting data exists partly due to the fact that the
identification of such attenuated virus strains in vivo is
limited to small numbers of subjects and that sequence
analyses have often been based on analyzing cellular
proviral DNA, thus possibly also including some lev-
el of grave-yard sequences. Today, with more sensi-
tive assays, some elite controllers have been shown to
have persistent viral replication detectable in plasma at
levels below 50 copies/ml [23]. In addition, a recent
report by Miura et al for instance did not reveal any
gross genetic defects in HIV-1 coding gene sequences
derived from plasma viral RNA from a large cohort of
elite controllers [24]. This observation suggests that
active viral suppression by the immune system rather
than shared viral genetic defects or polymorphisms is
driving viral control in HIV controllers. This conclu-
sion is also in line with work on accessory genes from
HIV controllers, where replication-competent viruses
from CD4+ T-cell co-culture supernatants were ana-
lyzed and did not reveal any consistent defects in either
vpr or vif genes [25].
4. Impact of host genetics on in vivo  HIV control
An extensive number of host genetic markers have
been identified over the last 20 years that are associat-
ed with either rapid or slow HIV disease progression
or with protection from infection. Many older studies
however were carried out using single gene approaches
with small number of samples and the genetic associ-
ations found were not always confirmed in subsequent
functional studies. Thanks to the advances of the Hu-
mane Genome Project, the use of whole-genome as-
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sociation scans, and the establishment of international
consortia such as CHAVI, EuroCHAVI or the HIV In-
ternational Controllers consortium, it has been possi-
ble to uncover certain genetic factors that might play a
relevant role in the control of HIV. This availability of
large samples number and the possibility to sequence
650,000 single-nucleotide polymorphisms within the
human genome should further enhance studies exam-
ining the contribution of multiple genetic factors [26].
However, unlike studies on genetic markers associat-
ed with for instance autoimmune diseases, the search
for host genetic polymorphisms in HIV infection al-
so needs to take into consideration the viral diversi-
ty in regions of different host genetics/ethnicities. An
earlier report on the effect of a single genetic (HLA)
marker and viral evolution has recently been confirmed
in a massive international effort, demonstrating the
inter-relationship between host genetics and viral evo-
lution [27,28]. These findings highlight that viral di-
versity is likely be shaped by differences in the fre-
quency of different host genetic markers and, based on
viral evolution, can lead to opposite effects of a specif-
ic genetic marker on HIV disease control [27]. Thus,
whole human genome approaches are severely com-
plicated by viral diversity in different host ethnicities
making comparisons across different clades of HIV and
various geographically distinct human populations dif-
ficult. This consideration also points to the possibili-
ty that different clades of HIV may possess inherently
different replication fitness and may drive disease de-
velopment at variable levels, as recently considered as
a possibly contributing factor in a case of severe acute
HIV infection [29].
5. Association of HLA polymorphisms with HIV
disease outcome
Many host genetic polymorphisms associated with
levels of disease control involve genes encoding for re-
ceptors for viral entry and molecules expressed on the
surface of cells of the innate or acquired immune sys-
tem, such as HLA, CCR5 and KIR receptors. More-
over, it seems that in some cases their potential protec-
tive influence might have a cumulative effect as seen for
the synergic effect of some KIR receptors and HLA-B
complexes [30]. Likely the most robust analyses have
focused on the HLA genes and their polymorphisms.
The HLA class genes form highly polymorphic loci in
the Major Histocompatibility Complex (MHC) located
in the short arm of chromosome 6 and encode for cel-
lular surface molecules that present foreign antigenic
epitopes to T lymphocytes. There are two groups of
HLA molecules including HLA class I and HLA class
II antigens. The HLA class I molecules are divided
into HLA-A, HLA-B, HLA-C all of which bind pep-
tides derived from intracellularly processed proteins
and present them to CD8+ cytotoxic T-cell lympho-
cytes (CTL). Among these, the HLA-B alleles, while
most diverse (more than 1,000 HLA-B alleles have
been identified to date) have also been shown to carry
the bulk of the anti-viral T cell immune response in
HIV infection [31]. Accordingly, the number of well-
defined HLA-B restricted epitopes exceeds the number
of defined epitopes restricted by HLA-A and, particu-
larly, HLA-C alleles. However, especially the HLA-C
alleles are currently under more intensive investigation
as larger HIV infected cohorts with more complete and
high-resolution HLA-C typing have become available.
HLA alleles are grouped into 9 supertypes based
on their structure, peptide-binding motif, epitope rep-
resentation and sequence similarity [32,33]. Particu-
larly alleles included in the HLA-B7 (B*5101, B81),
HLA-B27 (HLA-B27, B*1503) and HLA-B58 super-
types (HLA-B57, B*5801, B*1516, B*1517) have
been associated with improved or impaired levels of
HIV control. Of note, almost all the alleles in the
HLA-B58 supertype appear to mediate superior con-
trol of HIV infection [34]; with the exception being the
HLA-B*5802 allele, which is highly prevalent in South
Africa and which is associated with elevated median
viral loads [35]. The reasons how subtle changes in
the HLA sequence (HLA-B*5802 only differs in three
amino acids from the “good” HLA-B*5801 allele) can
so profoundly affect HIV disease outcome are still un-
clear and are not in all cases simply attributable to dif-
ferent CTL epitope repertoires presented on these alle-
les [35,36]. The fact that this allele, as well as the HLA-
B*1503 allele are present at high frequency and are
both associated with higher viral loads in HIV infect-
ed individuals (HLA-B*1503 is a “good” allele in the
North American population where it is rare; ref [27])
is in line with earlier reports that found an advantage
of expressing rare HLA supertype alleles in controlling
HIV [37].
In addition to HLA allele frequency,the homocygous
expression of individual HLA alleles has been associat-
ed with reduced viral control. This heterozygote advan-
tage has been widely observed in several cohorts, in-
cluding Caucasian and non-Caucasian populations [38,
39] and has been reproduced in Hepatitis C infection
for which HLA-associated markers of viral clearance
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and virus control have been identified as well [40]. Fur-
thermore, the effects of particular HLA supertypes or
of individual alleles have also been reported to provide
the basis for immunologically mediated resistance to
infection [41,42]. It will be interesting to confirm the
potential protective effects of such alleles in additional
cohorts with variable allele frequencies and to assess
other mechanisms and markers present in genetic link-
age to these alleles that may possibly be involved to at
least some levels in protection from HIV infection [43].
Associations between HIV control and specific poly-
morphisms in the HLA class II loci have been less well-
defined, maybe reflecting a possibly only indirect anti-
viral effect of HLA class II restricted CD4+ T cells.
Nevertheless, some cohort-based studies have reported
that DRB1*13 allele expression is associated with par-
tial protection from HIV disease progression, although
this has not consistently been observed [44]. The
DRB1*13/DRQ1*06 haplotype has also been found
at increased frequency in individuals who were treat-
ed early in HIV infection and who maintained virus
suppression after treatment interruption [45]. Further-
more, a protective role of DQB1*06 alleles, irrespective
of their DR haplotype co-expression, has been identi-
fied [46]. While the HLA class II associations have
not produced as strong markers as HLA class I analy-
ses, the representative studies given above highlight the
importance to further explore the contribution of the
specific CD4+ T cell responses and their genetic basis
in the control of HIV.
6. Specific HLA class I B alleles associated with
variable levels of HIV control
HLA-B*5701 and, to a lesser extent HLA-B27 are
HLA-B alleles overrepresented in North American and
European cohorts of LTNP and EC individuals [26,38,
39,47,48] and reviewed in [49]). Similarly, the HLA-
B*5703 allele (which is the prevalent B57 subtype in
Africans) is also significantly enriched among African
subjects that control HIV replication [31,50]. These as-
sociations are further supported by survival analyses of
HLA-B57 and HLA-B27 expressing individuals [51].
How these alleles mediate their beneficial effect has
however not been entirely clear, although in the case
of HLA-B27 and HLA-B57 compelling evidence sug-
gests it may be due to their presentation of multiple
immunodominant epitopes located in HIV Gag and re-
verse transcriptase [5,52,53]. The broad epitope reper-
toire and the wide cross-recognition of epitope vari-
ants presented by HLA-B57 suggest that effective viral
escape from HLA-B57 restricted CTL responses may
be difficult to achieve. Of note, HLA-B*5701 is in
strong linkage disequilibrium with the polymorphism
located in the HLA complex P5 gene (HCP5), located
100 kb centromeric from the HLA-B locus and who
has been identified as a protective marker of HIV infec-
tion, independent HLA-B57 expression [26]. Howev-
er, the mechanistic explanation of this protective effect
remains elusive and probably is a result of a combined
haplotypic effect with HLA-B*5701. This is also in
agreement with recent studies showing significant fit-
ness cost of HIV escape variants that affect HLA-B57
restricted CTL epitopes [54]. Similar results have re-
cently also been reported for CTL responses targeting
HLA-B13 restricted epitopes, which support the notion
that the nature of the presented epitope, more than the
restricting HLA molecule allele may determine the ben-
eficial effects of a specific HLA allele [27,55]. Howev-
er, evolutionarily closely related alleles with subtle se-
quence differences and comparable binding motifs but
associated with opposite rates of HIV disease progres-
sion also indicate that the presenting HLA molecule
may have a modulating effect on the effectiveness of
the restricted T cell response.
Analogous to the HLA-B58 and -B13 alleles above,
the protective effect of HLA-B27 allele is also thought
to be due to its restriction of an immunodominant CTL
response to a conserved HIV epitope located in p24
Gag. This 10mer epitope sequence contains the argi-
nine residue at position 264 of HIV Gag which, once
mutated weakens the epitope binding to HLA-B27 [56].
However, the classical mutation to lysine has detrimen-
tal effects on viral replication capacity and requires
a complex series of compensatory mutations in part-
ly distant sites in Gag to restore viral fitness [57–59].
Thus, the mutation is less likely to revert and to restore
full replication fitness and individuals with the escape
mutation may still present with lower viral loads than
the rest of the population.
Apart from HLA alleles that mediate relative protec-
tion from HIV disease progression, a number of alle-
les have been identified that are linked to accelerated
disease courses. Among these, the HLA-B35/Cw04
haplotype has been consistently found at increased lev-
els in individuals with rapid progression to AIDS [38].
Subsequent studies revealed different peptide-binding
specificities for the various HLA-B35 subtypes, which
prompted their discrimination into Py and Px alleles,
respectively [36]. Accelerated HIV disease progres-
sion has been associated with the HLA-B35 Px (HLA-
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B*3502/3503/3504) alleles but not Py alleles (B*3501).
This could explain why HLA-B35 associations were
not observed in African-Americans as this ethnic group
often expresses HLA-B35-Py alleles. It has also been
suggested that the HLA-Cw04 association with rapid
disease progression was due to its linkage disequilib-
rium with HLA-B35-Px alleles rather than exerting a
deleterious effect by itself [36].
Aside from HLA linkage disequilibrium and other
polymorphisms in the MHC region, the potentially syn-
ergistic effects of specific HLA type and NK inhibitory
receptor (KIR) have recently obtained much attention.
KIR receptors are polymorphic receptors that interact
with HLA class I molecules and regulate the NK ac-
tivity, either by mediating activating or inhibitory sig-
nals. A number of studies have associated the expres-
sion of specific HLA and KIR combinations with dif-
ferent diseases, such as cervical neoplasia and infec-
tious diseases, including HIV [30,60–62]. The insight
into potential mechanisms of these favorable combi-
nations is most advanced in the case of HLA-B/KIR
allele combinations. HLA-B molecules contain one of
two mutually exclusive serological epitopes, Bw4 and
Bw6, which differ by five amino acids spanning posi-
tions 77-83 of the HLA-B heavy chain, including the
crucial Isoleucine residue at position 80 [63]. HLA-
Bw4- but not HLA-Bw6-molecules have been consid-
ered ligands for KIR3DL1 and possibly KIR3DS1 [62,
64,65]. In a proportional hazard model that included
all known genetic predictors of HIV progression, co-
expression of KIR3DS1 and HLA-Bw4 was found to
be an independent predictor of decreased time to AIDS.
Interestingly, this beneficial effected was observed de-
spite the fact that KIR3DS1 alone in the absence of
its HLA ligand was associated with more rapid disease
progression. Thus, the findings highlight the poten-
tial for KIR/HLA interactions to be important indepen-
dent predictors of HIV progression and may help shed
light on the relative contribution of these interactions
compared to HLA-restricted CTL activity [62,66].
7. Non-MHC encoded genetic markers of HIV
control
Although the CD4 antigen is the main receptor for
HIV entry into susceptible cells, effective viral infec-
tion requires the presence of one of two major co-
receptors, referred to as CCR5 and CXCR4, respec-
tively. These two co-receptors belong to the superfam-
ily of 7-transmembrane G-protein–coupled chemokine
receptors and determine viral tropism, allowing for the
differentiation of R5, X4 or R5/X4 viruses that can use
either one or both of these receptors [67,68].
Chemokines are a superfamily of small molecules
(8–15 kDa) that exert many roles in inflammatory and
in homeostatic immune processes [69,70]. They are di-
vided into four subfamilies based on the structural cys-
teine motif located in the amino-terminus of the mature
protein (CXC, CC, CX3C and C chemokines) and their
receptor usage shows a considerable level of redun-
dancy [71]. The chemokine Regulated on Activation
Normal T-cell Expressed and Secreted (RANTES or
CCL5), Macrophage Inflammatory Protein-1α (MIP-
1α or CCL3) and 1β (MIP-1β or CCL4), were first
identified as natural ligands for the CCR5 receptor and
were subsequently shown to be potent inhibitors of R5
viruses in vitro. The natural ligand of CXCR4 is Stro-
mal Cell Derived Factor-1 (SDF-1 or CXCL4), which
also possesses potent inhibitor function of X4 viruses
in vitro [72–74]. Other chemokine receptors that can
act as HIV co-receptors have been described, including
CCR3, CCR2b and CCR8 [75].
Shortly after their identification as crucial HIV
co-receptors, genetic polymorphisms in the various
chemokine receptors were reported. In particular, a 32
base pair deletion in the CCR5 gene (CCR5-∆32) was
identified that generates a non-functional protein that
is not expressed on the cell surface. The homocygous
expression of the CCR5-∆32 variant provides in vivo
resistance to infection by R5 HIV isolates. These ob-
servations were made in different cohorts of men who
have sex with men and hemophiliacs with documented
exposure to HIV. When present in a single copy only,
the heterocygous expression of the wildtype CCR5 re-
ceptor was found to be sufficient to enable infection,
although the lower levels of CCR5 on the cell surface
were associated with reduced viral replication and a
delayed onset of AIDS [76–79]. Spurred by the effects
of heterocygous expression of CCR5-∆32, mutations
in the promoter region of CCR5 were identified that
are also associated with altered transmission or delayed
disease progression, although to a lesser extent than the
CCR5-∆32 mutation [80,81].
In addition to the CCR5-∆32 mutation, the V64I
substitution in the CCR2A protein sequence (CCR2-
V64I) has also been found to delay HIV disease pro-
gression; however without preventing HIV transmis-
sion. Intriguingly, CCR2 is rarely used as a co-receptor
in HIV infection and its impact on global epidemic is
unclear. Furthermore, it has been demonstrated that
the CCR2-V64I allele is in strong linkage disequilibri-
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um with a point mutation in the CCR5 regulatory re-
gion [82]. Together with CCR5 mutations, approxi-
mately 29% of LTNP phenotypes in large cohorts have
been estimated to be due to a mutant genotype for CCR2
or CCR5 [83]. Interestingly though, relative protection
against AIDS provided by CCR5-∆32 heterocygosity
appears to be continuous during HIV disease over time,
whereas the protective effects of the CCR2-64I variant
was most pronounced in early infection [84].
The identification of CCR5 and CCR2 as crucial
molecules for HIV-infection has also offered new treat-
ment targets to inhibit viral replication and CCR5-based
HIV entry-inhibitors have been developed are now part
of effective rescue treatment strategies [85,86]. More
recently, a single case of stem-cell transplantation from
an homocygous CCR5-∆32 donor to an HIV-infected
individual with acute myeloid leukemia showed no
signs of rebounding viremia in plasma, bone marrow or
rectal mucosa 20 months post-transplantation and in the
absence of antiretroviral treatment. This is even more
surprising given that minor X4-variants were identified
in the pre-transplantation viral population, giving rise
to a number of questions on how viral populations with
different cell tropism are controlled in vivo [87].
Polymorphisms involving other chemokine recep-
tors and/or other chemokine receptor ligands have
been identified as well. Especially, plasma levels of
RANTES, which can significantly vary among healthy
individuals, were found to be modulated by two single
nucleotide polymorphisms in the RANTES gene pro-
moter region. These changes have also been associated
with delayed progression of HIV disease and experi-
mental over-expression and increased promotor activity
of RANTES functionally link the polymorphisms with
reduced HIV replication capacity as a consequence of
increased RANTES production [88–90]. Similarly, a
genetic variant consisting of a transition (G-A) in the
3’untranslated region of the SDF-1 gene (SDF-1 3’A)
has also been associated with a delay in AIDS onset
when present as homocygous variant. Its underlying
mechanism and effect on X4 viral populations in vivo
is however not well understood [91–94]. Noteworthy,
no mutations in the CXCR4 receptor gene have been
proposed as markers of relative HIV control, probably
because CXCR4 and SDF-1 are essential at embryonic
development stages and, consequently, such mutations
might be potentially lethal [95].
A genetic determinant that has recently been associ-
ated with rate of HIV disease progression is the copy
number of the chemokine gene CCL3L1 (MIP-1α). In-
dividuals with higher CCL3L1 copy numbers than the
population race-adjusted average showed lower steady-
state viral load; suggesting an increased rate of HIV dis-
ease progression in subjects with lower CCL3L1 copy
number [96].
Finally, several polymorphisms in the DC-SIGN
(dendritic cell specific intracellular adhesion molecule
-3-grabbing nonintegrin, i.e. CD209) promoter have
been found to be linked to an increase or decrease in
susceptibility to HIV infection, particularly also in par-
enterally acquired HIV infection [97]. As DC-SIGN
has also been associated with tuberculosis infection
and disease outcome, studies such as a recent one in
an Indian population, may help employing DC-SIGN
based strategies for the combined fight against these
two major human pathogens [98].
8. Immune markers in the relative control of HIV
infection
An extensive amount of data indicates a potentially
crucial role of HIV-specific cellular and humoral im-
mune responses in the in vivo control of viral replica-
tion and HIV disease progression. As discussed above,
a number of host genetic markers have been identified,
particularly specific HLA class I alleles, suggesting an
important contribution of the HLA class I restricted
CD8+ T-cell immunity in virus control. Despite an
increasingly more detailed understanding of the inter-
play between host immunity, viral evolution and the
impact on viral control, clearly defined immune corre-
lates of controlled HIV infection remain elusive. As a
consequence, effective vaccine design is still hampered
by the availability of well-defined immune parameters
that actively mediate in vivo viral control. While much
of the current investigations focus on the detailed char-
acterization of individuals with exceptional ability to
control their virus, it is important to notice that the im-
mune markers associated with this control can often
be biased towards subjects expressing specific host ge-
netics and are thus not necessarily translatable to the
general population. Nevertheless, a number of specific
characteristics of the host immunity against HIV that
have been identified clearly extend beyond these limi-
tations and will provide important guidance to vaccine
development and offer new immune-based therapeutic
treatment options.
9. HIV disease markers associated with
virus-specific cellular and humoral immunity
It is generally believed that the cytotoxic T cell (CTL)
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immune response contributes strongly to the in vivo
control of viral control. Virus-specific CTL responses
have been temporally associated with the initial decline
in plasma viremia after acute HIV infection and are
thought to determine viral set point in chronic stages
of infection [99,100]. This is supported by studies in
the SIV macaque model, where transient depletion of
the total CD8+ T-cell population in controller animals
resulted in 100- to 10,000-fold increases in viremia and
where the re-establishment of the CD8+ T-cell popu-
lations restored the ability of these animals to control
SIV replication [101,102]. Further support for an im-
portant role of virus-specific CTL in HIV control stems
from older studies conducted when tetramer technolo-
gy became first available in the late 1990ties [103]. The
use of such tetramer complexes allowed for the direct
ex vivo visualization of epitope-specific CTL popula-
tions and analysis of specific responses against defined
epitopes, without prior in vitro expansion and modu-
lation of epitope-specific T cells [104]. Initial analy-
ses using SL9 (SLYNTVATL, HIV Gag p17) specific
tetramers, revealed a significant inverse correlation be-
tween SL9-specific CTL frequency and plasma RNA
viral loads [105]. These analyses were however only
based on a limited number of SL9-responding subjects
and did not take into consideration the possibly im-
paired functionality of tetramer-specific T cells. Not
surprisingly, the SL9 association with HIV control were
not confirmed in studies that used in vitro expanded T
cells, possibly due to the differential ability of such cells
to expand in vitro [106]. Since these earlier studies,
novel assays, including the IFN-γ based ELISpot assay
and in vitro inhibition assays first developed by Yang
et al. [107,108] provide additional tools to assess di-
rect ex vivo T cell activity and functionality [109,110].
These analyses further support the relevance of HIV
specific T cells in HIV control, although in many stud-
ies, the precise phenotypic and functional markers of
these virus-specific T-cell responses attributed to viral
control may reflect the effects rather then the cause of
otherwise controlled HIV infection. Dissecting these
two possibilities and assigning unambiguously causal-
ity to specific immune markers and T cell specifici-
ties remains one of the currently biggest challenges
in defining functionally relevant immune correlates of
HIV control.
Over the years, an number of studies have correlat-
ed strong and broad HIV-specific T-cell responses with
the delayed progression to AIDS and vaccine success
is oftentimes subjected to a quantification of the total
breadth and magnitude of induced responses. While
a detail characterization of vaccine-induced responses
will always need to be conducted, it is also clear from
a growing number of reports [111] that total virus spe-
cific immunity is not necessarily the best measure of
in vivo immune control of HIV and that more detailed
analyses of these responses are needed. Indeed, re-
analyses of earlier total-virus specific CTL data sug-
gest that T-cell responses preferentially targeting Gag
or other highly conserved epitopes are most relevant
specificities for the enhanced antiviral efficacy of T-
cells seen in those individuals [109,112]. On the other
hand, CTL responses against Env or accessory and reg-
ulatory proteins have been shown to have the opposite
effect, and are directly correlated with elevated viral
load [50]. These findings are in line with more recent
studies in clade B as well as clade C infection and anal-
yses that either assessed total viral immunity in peptide
pools rather than individual peptide preparations or that
focused on responses restricted by specific individual
HLA alleles only [50,52,113–117].
However and despite strong associations between
Gag-specific T cell immunity and relative HIV con-
trol, the causative relationship between the observed
response patterns and viral control is still outstanding.
Plausible explanations for how dominant Gag specific
cytotoxic T-cells could mediate relative virus control
stem from the ability of certain HLA class I molecules
such as HLA-B57 to present a broad number of HIV
Gag peptides and to induce high-magnitude CD8+ T-
cell responses in early infection [52,113]. In addition,
rapid re-presentation of epitopes derived from the Gag
proteins contained in the incoming, infecting virus par-
ticles (possibly within less than 2hr after infection) may
provide Gag-specific T cells with a decisive advantage
to eliminate infected cells before massive virus produc-
tion has been initiated [118]. However, not all domi-
nant Gag-protein specific responses may be equally ef-
fective and comparative studies in clade C and B infec-
tion have identified subdominant Gag responses as well
as responses outside of Gag as crucial components in
relative virus control [27]. The important role of sub-
dominant responses has also been confirmed in studies
in the SIV macaque model and is also supported by the
detection of subdominant CTL responses in groups of
HEPS [11,101].
Apart from CTL specificity, the in vivo antiviral ef-
ficacy of HIV-specific CD8+ T-cell immunity has al-
so been tightly linked to the functional competence of
these responses. In particular, proliferative capacity
with high perforin expression and secretion of multiple
cytokines such as IFN-γ, IL-2, TNF-α, MIP-1b and/or
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CD107a surface expression after antigen contact char-
acterize the responses seen in LTNP [119,120]. In ad-
dition to polyfunctionality, the avidity of virus-specific
T-cell responses is also considered a potentially im-
portant measure of an effective immune response and
has been shown in HCV infection, to be associated
with viral clearance and higher levels of cross-variant
recognition [121,122]. Thus, the quality of the CD8+
T-cell response to HIV serves as a better marker of
controlled infection than the quantity (i.e. breadth and
magnitude) of these responses. In addition, a HLA-
DR+, CD38- activation CD8+ T-cell phenotype was
more frequently found among virus-specific T-cells in
HIV controllers than in non-controllers and may rep-
resent a T cell population with superior ability to ex-
pand upon exposure to antigen and capacity to exert
effector functions [110]. Whether full-differentiation
into CCR7-/CD45- effector cells and broad functional
CTL is only a hallmark of controlled HIV infection in
the peripheral PBMC compartment or also extends to
CTL in gut-associated lymphoid tissue -where massive
initial depletion of CD4+ T-cells occurs- remains an
open question. Nevertheless, a rapidly growing set of
reports dealing with the emergence and accumulation
of CTL escape mutations under appropriate CTL pres-
sure, the transmission of “escaped” variants, implica-
tions of fitness costs incurred by CTL escape muta-
tions and the global adaptation of HIV to HLA class I
polymorphisms further document the crucial role that
HIV-specific CTL overall play in the control of HIV
infection [28,54,58,123–130].
An additional factor for an effective CD8+ T-cell
response includes the presence and function of CD4+
‘helper’ T-cells. HIV-specific CD4+ T-cell population
have been shown to be required for long-term mainte-
nance of antigen-specific CD8+ memory T-cells, both
in the human setting as well as in the monkey mod-
el [101,131–133]. The relevance for functional CD4+
T-cell help in the maintenance of effective CTL pop-
ulations has recently also been reported for viral in-
fections other than HIV, including EBV and CMV in-
fections [134,135]. The potential importance of virus-
specific T helper cell activity is further highlighted
by studies that have associated the presence of gp41-
specific antibodies with CD4+ T-cell responses to Gag-
p24 [136,137]. Regardless of the well-documented
anti-viral effects of neutralizing Ab responses [138]
general antibody-responses have not emerged as strong
markers of HIV control. Some of the existing data
have been inconsistent as some studies have associat-
ed higher titers of heterologous nAb in LTNP whereas
more recent studies indicate the presence of lower Nab
activity among elite controllers [5,16,139]. It will be
interesting to investigate whether possible residual vi-
ral replication in the former group of patients may drive
additional Ab production or whether additional, unac-
counted factor and assay differences are responsible for
the observed differences.
10. Innate immunity
During primary HIV infection, there is a massive
destruction of the CD4+ T-cell population in the gut-
associated lymphoid tissue (GALT) impairing local cel-
lular immunity at mucosal sites and causing translo-
cation of microbial products which in turn contributes
to a deleterious persistent inflammation [140,141,143].
The potential damaging effects of chronic inflammation
by continuous bacterial translocation are also highlight-
ed by similar studies in HCV infection, where it has
been implicated in the progression to advanced stages
of cirrhosis [144]. Most importantly however, the mas-
sive depletion of CD4+ T-cells, general inflammation
and immune activation occur at times when the adaptive
immune system has not mounted an effective immune
response yet. As mentioned above, some markers as-
sociated with the innate immune system, particularly
KIR and Toll-like receptors (TLR) have been associ-
ated with variable levels of HIV control in these early
stages of infection. As such, recent host genetic studies
indicate that individuals co-expressing KIR3DS1 and
HLA-Bw4-80I (family of HLA alleles that presumably
bind to KIR3DS1 and activate NK cells) have lower
viral loads and show a reduced risk of progression to
AIDS [62,145]. In addition, polymorphisms in toll-like
receptor 9, which mediates innate immune response
against DNA motifs common in bacteria and viruses,
have recently been shown to impact clinical outcomes
as well [146]. However, significant functional data
supporting the innate immunity and its linkage to dis-
ease pathogenesis is still scarce and needs to be further
explored. In addition, extensive cohorts of individuals
captured in earliest period of acute HIV infection will
need to be comprehensively studied to assess the impact
of these markers on initial peak viremia and the level
of CD4+ T-cell depletion. However, the recent identi-
fication of immune memory mediated by NK cell pop-
ulations may offer novel approaches for preventative
and therapeutic interventions in HIV infection [147].
11. Conclusions and implications for vaccine
design
Control of viral replication in HIV infection is a mul-
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tifactorial process. Polyfunctional CD8+ T-cell immu-
nity against particular viral proteins along with virus-
reactive CD4+ T-cell help have been most consistently
implicated in modulating HIV infection in vivo. Viral
factors such as specific mutations often emerging as a
consequence of immune selection pressure and entire
gene segment deletions have also been associated with
reduced viral burden and slower progression of HIV
disease. In addition, specific host genetic markers, par-
ticularly HLA, has been most compellingly linked to
relative control of HIV replication. While such host
genetic markers may provide great help in understand-
ing the (immune)-pathologyof HIV, they will likely not
be directly informative for HIV vaccine development.
However, they can guide vaccine immunogen design,
although care needs to be taken that such immunogen
design is not overly guided by observations made in
individuals with favourable host genetics. To avoid the
resulting vaccine product to be tailored unreasonably
strongly towards individuals with beneficial genetics,
subjects who do not express these markers yet control
HIV on their own will be most informative. In addition,
while immune parameters that could mediate steriliz-
ing immunity, i.e. resistance to infection, still need to
be defined, the development of vaccines that are able to
induce partial in vivo control, albeit not prevent infec-
tion, would have significant impact on individual health
by slowing HIV disease progression and would help
to contain the HIV pandemic by reducing transmission
rates.
In this regard, the early assessments of vaccine suc-
cess in phase I and phase II trials will be based on
immune read-outs, rather than prevention of infection
(which would be the central end-point in a phase IIb/III
trial). Thus, the definition of precise immune correlates
of controlled HIV infection is crucial since vaccine in-
duced responses will be compared to these parame-
ters. If their definition is flawed or represents epiphe-
nomena of otherwise controlled HIV infection, valu-
able vaccine candidates may be discarded premature-
ly. Together with immune parameters of controlled in-
fection, the identification of host genetic markers may
in the future facilitate the design of gene therapy ap-
proaches that would try to either block expression of un-
favourable genes or introduce beneficial components.
Although not based on gene-therapy, the case of the
CCR5-∆32 stem-cell transplanted individual referred
to above, points towards the potential feasibility of such
approaches.
Acknowledgments
Financial support: Supported in part by the Red
de Investigación de Sida (RIS) (RD06/04). Instituto de
Salud Carlos III, Madrid, Spain and HIVACAT.
Potential conflict of interest: None.
References
[1] UNAIDS. 2008. Report on the global HIV/AIDS epidemic.
In.
[2] Watkins, K. 2005. Human Development Report (UNDP). In
United Nations Development Program.
[3] S.P. Buchbinder, M.H. Katz, N.A. Hessol, P.M. O’Malley
and S.D. Holmberg, Long-term HIV-1 infection without im-
munologic progression, AIDS 8 (1994), 1123–1128.
[4] M.R. Betts, D.R. Ambrozak, D.C. Douek, S. Bonhoeffer,
J.M. Brenchley, J.P. Casazza, R.A. Koup and L.J. Pick-
er, Analysis of total human immunodeficiency virus (HIV)-
specific CD4(+) and CD8(+) T-cell responses: relationship
to viral load in untreated HIV infection, J Virol 75 (2001),
11983–11991.
[5] F. Pereyra, M.M. Addo, D.E. Kaufmann, Y. Liu, T. Miura,
A. Rathod, B. Baker, A. Trocha, R. Rosenberg, E. Mackey,
P. Ueda, Z. Lu, D. Cohen, T. Wrin, C.J. Petropoulos, E.S.
Rosenberg and B.D. Walker, Genetic and immunologic het-
erogeneity among persons who control HIV infection in the
absence of therapy, J Infect Dis 197 (2008), 563–571.
[6] S. Rowland-Jones, J. Sutton, K. Ariyoshi, T. Dong, F. Gotch,
S. McAdam, D. Whitby, S. Sabally, A. Gallimore, T. Cor-
rah et al., HIV-specific cytotoxic T-cells in HIV-exposed but
uninfected Gambian women, Nat Med 1 (1995), 59–64.
[7] J.M. McNicholl and N. Promadej, 2004. Insights into the role
of host genetic and T-cell factors in resistance to HIV trans-
mission from studies of highly HIV-exposed Thais, Immunol
Res 29 (1995), 161–174.
[8] Y. Wang, X. Wang, J. Peng, L. Chen, J. Cheng, S. Nie, T.
Feng, G. Zhao, J. Zhao and X. Shi, Short communication:
SDF1-3’A gene mutation is correlated with increased suscep-
tibility to HIV type 1 infection by sexual transmission in Han
Chinese, AIDS Res Hum Retroviruses 24 (2008), 1341–1345.
[9] T. Hirbod, K. Broliden and R. Kaul, Genital immunoglobulin
A and HIV-1 protection: virus neutralization versus speci-
ficity, AIDS 22 (2008), 2401–2402.
[10] T. Hirbod, R. Kaul, C. Reichard, J. Kimani, E. Ngugi, J.J.
Bwayo, N. Nagelkerke, K. Hasselrot, B. Li, S. Moses, K.S.
MacDonald and K. Broliden, HIV-neutralizing immunoglob-
ulin A and HIV-specific proliferation are independently asso-
ciated with reduced HIV acquisition in Kenyan sex workers,
AIDS 22 (2008), 727–735.
[11] R. Kaul, T. Dong, F.A. Plummer, J. Kimani, T. Rostron,
P. Kiama, E. Njagi, E. Irungu, B. Farah, J. Oyugi, R.
Chakraborty, K.S. MacDonald, J.J. Bwayo, A. McMichael
and S.L. Rowland-Jones, 2001. CD8(+) lymphocytes re-
spond to different HIV epitopes in seronegative and infected
subjects, J Clin Invest 107 (2008), 1303–1310.
[12] K. Broliden, J. Hinkula, C. Devito, P. Kiama, J. Kimani, D.
Trabbatoni, J.J. Bwayo, M. Clerici, F. Plummer and R. Kaul,
2001. Functional HIV-1 specific IgA antibodies in HIV-1
exposed, persistently IgG seronegative female sex workers,
Immunol Lett 79 (2008), 29–36.
B. Mothe et al. / Virological, immune and host genetics markers in the control of HIV infection 115
[13] S.L. Rowland-Jones, S. Pinheiro, R. Kaul, P. Hansasuta, G.
Gillespie, T. Dong, F.A. Plummer, J.B. Bwayo, S. Fidler, J.
Weber, A. McMichael and V. Appay, How important is the
‘quality’ of the cytotoxic T lymphocyte (CTL) response in
protection against HIV infection? Immunol Lett 79 (2001),
15–20.
[14] R.E. Horton, T.B. Ball, C. Wachichi, W. Jaoko, W.J. Ruther-
ford, L. McKinnon, R. Kaul, A. Rebbapragada, J. Kimani
and F.A. Plummer, Cervical HIV-specific IgA in a population
of commercial sex workers correlates with repeated exposure
but not resistance to HIV, AIDS Res Hum Retroviruses 25
(2009), 83–92.
[15] A. Suy, P. Castro, M. Nomdedeu, F. Garcia, A. Lopez, E.
Fumero, T. Gallart, L. Lopalco, O. Coll, J.M. Gatell and M.
Plana, Immunological profile of heterosexual highly HIV-
exposed uninfected individuals: predominant role of CD4
and CD8 T-cell activation, J Infect Dis 196 (2007), 1191–
1201.
[16] Y. Cao, L. Qin, L. Zhang, J. Safrit and D.D. Ho, Virologic
and immunologic characterization of long-term survivors of
human immunodeficiency virus type 1 infection, N Engl J
Med 332 (1995), 201–208.
[17] B. Joos, M. Fischer, H. Kuster, S.K. Pillai, J.K. Wong, J.
Boni, B. Hirschel, R. Weber, A. Trkola and H.F. Gunthard,
HIV rebounds from latently infected cells, rather than from
continuing low-level replication, Proc Natl Acad Sci U S A
105 (2008), 16725–16730.
[18] N.J. Deacon, A. Tsykin, A. Solomon, K. Smith, M. Ludford-
Menting, D.J. Hooker, D.A. McPhee, A.L. Greenway, A.
Ellett, C. Chatfield, V.A. Lawson, S. Crowe, A. Maerz, S.
Sonza, J. Learmont, J.S. Sullivan, A. Cunningham, D. Dwyer,
D. Dowton and J. Mills, Genomic structure of an attenuated
quasi species of HIV-1 from a blood transfusion donor and
recipients, Science 270 (1995), 988–991.
[19] O. Schwartz, V. Marechal, S. Le Gall, F. Lemonnier and
J.M. Heard, Endocytosis of major histocompatibility com-
plex class I molecules is induced by the HIV-1 Nef protein,
Nat Med 2 (1996), 338–342.
[20] M.J. Churchill, D.I. Rhodes, J.C. Learmont, J.S. Sullivan,
S.L. Wesselingh, I.R. Cooke, N.J. Deacon and P.R. Gorry,
Longitudinal analysis of human immunodeficiency virus type
1 nef/long terminal repeat sequences in a cohort of long-term
survivors infected from a single source, J Virol 80 (2006),
1047–1052.
[21] L. Alexander, E. Weiskopf, T.C. Greenough, N.C. Gaddis,
M.R. Auerbach, M.H. Malim, S.J. O’Brien, B.D. Walker,
J.L. Sullivan and R.C. Desrosiers, Unusual polymorphisms
in human immunodeficiency virus type 1 associated with
nonprogressive infection, J Virol 74 (2000), 4361–4376.
[22] A.K. Iversen, E.G. Shpaer, A.G. Rodrigo, M.S. Hirsch, B.D.
Walker, H.W. Sheppard, T.C. Merigan and J.I. Mullins, Per-
sistence of attenuated rev genes in a human immunodeficien-
cy virus type 1-infected asymptomatic individual, J Virol 69
(1995), 5743–5753.
[23] H. Hatano, E.L. Delwart, P.J. Norris, T.H. Lee, J. Dunn-
Williams, P.W. Hunt, R. Hoh, S.L. Stramer, J.M. Linnen,
J.M. McCune, J.N. Martin, M.P. Busch and S.G. Deeks,
Evidence for persistent low-level viremia in individuals who
control human immunodeficiency virus in the absence of
antiretroviral therapy, J Virol 83 (2009), 329–335.
[24] T. Miura, M.A. Brockman, C.J. Brumme, Z.L. Brumme, J.M.
Carlson, F. Pereyra, A. Trocha, M.M. Addo, B.L. Block,
A.C. Rothchild, B.M. Baker, T. Flynn, A. Schneidewind, B.
Li, Y.E. Wang, D. Heckerman, T.M. Allen and B.D. Walker,
Genetic characterization of human immunodeficiency virus
type 1 in elite controllers: lack of gross genetic defects or
common amino acid changes, J Virol 82 (2008), 8422–8430.
[25] A. Lamine, A. Caumont-Sarcos, M.L. Chaix, A. Saez-Cirion,
C. Rouzioux, J.F. Delfraissy, G. Pancino and O. Lambotte,
Replication-competent HIV strains infect HIV controllers
despite undetectable viremia (ANRS EP36 study), AIDS 21
(2007), 1043–1045.
[26] J. Fellay, K.V. Shianna, D. Ge, S. Colombo, B. Ledergerber,
M. Weale, K. Zhang, C. Gumbs, A. Castagna, A. Cossarizza,
A. Cozzi-Lepri, A. De Luca, P. Easterbrook, P. Francioli, S.
Mallal, J. Martinez-Picado, J.M. Miro, N. Obel, J.P. Smith, J.
Wyniger, P. Descombes, S.E. Antonarakis, N.L. Letvin, A.J.
McMichael, B.F. Haynes, A. Telenti and D.B. Goldstein, A
whole-genome association study of major determinants for
host control of HIV-1, Science 317 (2007), 944–947.
[27] N. Frahm, P. Kiepiela, S. Adams, C.H. Linde, H.S. Hewitt,
K. Sango, M.E. Feeney, M.M. Addo, M. Lichterfeld, M.P.
Lahaie, E. Pae, A.G. Wurcel, T. Roach, M.A. St John, M.
Altfeld, F.M. Marincola, C. Moore, S. Mallal, M. Carring-
ton, D. Heckerman, T.M. Allen, J.I. Mullins, B.T. Korber,
P.J. Goulder, B.D. Walker and C. Brander, Control of human
immunodeficiency virus replication by cytotoxic T lympho-
cytes targeting subdominant epitopes, Nat Immunol 7 (2006),
173–178.
[28] Y. Kawashima, K. Pfafferott, J. Frater, P. Matthews, R. Payne,
M. Addo, H. Gatanaga, M. Fujiwara, A. Hachiya, H. Koizu-
mi, N. Kuse, S. Oka, A. Duda, A. Prendergast, H. Crawford,
A. Leslie, Z. Brumme, C. Brumme, T. Allen, C. Brander, R.
Kaslow, J. Tang, E. Hunter, S. Allen, J. Mulenga, S. Branch,
T. Roach, M. John, S. Mallal, A. Ogwu, R. Shapiro, J.G.
Prado, S. Fidler, J. Weber, O.G. Pybus, P. Klenerman, T.
Ndung’u, R. Phillips, D. Heckerman, P.R. Harrigan, B.D.
Walker, M. Takiguchi and P. Goulder, Adaptation of HIV-1
to human leukocyte antigen class I, Nature (2009).
[29] J. Dalmau, M.C. Puertas, M. Azuara, A. Marino, N. Frahm,
B. Mothe, N. Izquierdo-Useros, M.J. Buzon, R. Paredes,
L. Matas, T.M. Allen, C. Brander, C. Rodrigo, B. Clotet
and J. Martinez-Picado, Contribution of immunological and
virological factors to extremely severe primary HIV type 1
infection, Clin Infect Dis 48 (2009), 229–238.
[30] R.M. Single, M.P. Martin, X. Gao, D. Meyer, M. Yeager,
J.R. Kidd, K.K. Kidd and M. Carrington, Global diversity
and evidence for coevolution of KIR and HLA, Nat Genet 39
(2007), 1114–1119.
[31] P. Kiepiela, A.J. Leslie, I. Honeyborne, D. Ramduth, C.
Thobakgale, S. Chetty, P. Rathnavalu, C. Moore, K.J. Pfaf-
ferott, L. Hilton, P. Zimbwa, S. Moore, T. Allen, C. Brander,
M.M. Addo, M. Altfeld, I. James, S. Mallal, M. Bunce, L.D.
Barber, J. Szinger, C. Day, P. Klenerman, J. Mullins, B. Kor-
ber, H.M. Coovadia, B.D. Walker and P.J. Goulder, Dominant
influence of HLA-B in mediating the potential co-evolution
of HIV and HLA, Nature 432 (2004), 769–775.
[32] A. Sette and J. Sidney, Nine major HLA class I supertypes
account for the vast preponderance of HLA-A and -B poly-
morphism, Immunogenetics 50 (1999), 201–212.
[33] J. Sidney, B. Peters, N. Frahm, C. Brander and A. Sette, HLA
class I supertypes: a revised and updated classification, BMC
Immunol 9(1) (2008).
[34] N. Frahm, S. Adams, P. Kiepiela, C.H. Linde, H.S. Hewitt,
M. Lichterfeld, K. Sango, N.V. Brown, E. Pae, A.G. Wurcel,
M. Altfeld, M.E. Feeney, T.M. Allen, T. Roach, M.A. St John,
E.S. Daar, E. Rosenberg, B. Korber, F. Marincola, B.D. Walk-
er, P.J. Goulder and C. Brander, HLA-B63 presents HLA-
116 B. Mothe et al. / Virological, immune and host genetics markers in the control of HIV infection
B57/B58-restricted cytotoxic T-lymphocyte epitopes and is
associated with low human immunodeficiency virus load, J
Virol 79 (2005), 10218–10225.
[35] K.C. Ngumbela, C.L. Day, Z. Mncube, K. Nair, D. Ram-
duth, C. Thobakgale, E. Moodley, S. Reddy, C. de Pierres,
N. Mkhwanazi, K. Bishop, M. van der Stok, N. Ismail, I.
Honeyborne, H. Crawford, D.G. Kavanagh, C. Rousseau, D.
Nickle, J. Mullins, D. Heckerman, B. Korber, H. Coovadia,
P. Kiepiela, P.J. Goulder and B.D. Walker, Targeting of a
CD8 T cell env epitope presented by HLA-B*5802 is asso-
ciated with markers of HIV disease progression and lack of
selection pressure, AIDS Res Hum Retroviruses 24 (2008),
72–82.
[36] X. Gao, G.W. Nelson, P. Karacki, M.P. Martin, J. Phair, R.
Kaslow, J.J. Goedert, S. Buchbinder, K. Hoots, D. Vlahov,
S.J. O’Brien and M. Carrington, Effect of a single amino acid
change in MHC class I molecules on the rate of progression
to AIDS, N Engl J Med 344 (2001), 1668–1675.
[37] E. Trachtenberg, B. Korber, C. Sollars, T.B. Kepler, P.T.
Hraber, E. Hayes, R. Funkhouser, M. Fugate, J. Theiler,
Y.S. Hsu, K. Kunstman, S. Wu, J. Phair, H. Erlich and S.
Wolinsky, Advantage of rare HLA supertype in HIV disease
progression, Nat Med 9 (2003), 928–935.
[38] M. Carrington, G.W. Nelson, M.P. Martin, T. Kissner, D.
Vlahov, J.J. Goedert, R. Kaslow, S. Buchbinder, K. Hoots and
S.J. O’Brien, 1999. HLA and HIV-1: heterozygote advantage
and B*35-Cw*04 disadvantage, Science 283 (2003), 1748–
1752.
[39] J. Tang, C. Costello, I.P. Keet, C. Rivers, S. Leblanc, E.
Karita, S. Allen and R.A. Kaslow, HLA class I homozygosity
accelerates disease progression in human immunodeficiency
virus type 1 infection, AIDS Res Hum Retroviruses 15 (1999),
317–324.
[40] P. Hraber, C. Kuiken and K. Yusim, Evidence for human
leukocyte antigen heterozygote advantage against hepatitis C
virus infection, Hepatology 46 (2007), 1713–1721.
[41] K.S. MacDonald, K.R. Fowke, J. Kimani, V.A. Dunand, N.J.
Nagelkerke, T.B. Ball, J. Oyugi, E. Njagi, L.K. Gaur, R.C.
Brunham, J. Wade, M.A. Luscher, P. Krausa, S. Rowland-
Jones, E. Ngugi, J.J. Bwayo and F.A. Plummer, Influence of
HLA supertypes on susceptibility and resistance to human
immunodeficiency virus type 1 infection, J Infect Dis 181
(2000), 1581–1589.
[42] F.A. Koning, C.A. Jansen, J. Dekker, R.A. Kaslow, N. Duk-
ers, D. van Baarle, M. Prins and H. Schuitemaker, Correlates
of resistance to HIV-1 infection in homosexual men with
high-risk sexual behaviour, AIDS 18 (2004), 1117–1126.
[43] S. Boulet, M. Kleyman, J.Y. Kim, P. Kamya, S. Sharafi,
N. Simic, J. Bruneau, J.P. Routy, C.M. Tsoukas and N.F.
Bernard, A combined genotype of KIR3DL1 high expressing
alleles and HLA-B*57 is associated with a reduced risk of
HIV infection, AIDS 22 (2008), 1487–1491.
[44] T. Ndung’u, S. Gaseitsiwe, E. Sepako, F. Doualla-Bell, T.
Peter, S. Kim, I. Thior, V.A. Novitsky and M. Essex, Major
histocompatibility complex class II (HLA-DRB and -DQB)
allele frequencies in Botswana: association with human im-
munodeficiency virus type 1 infection, Clin Diagn Lab Im-
munol 12 (2005), 1020–1028.
[45] U. Malhotra, S. Holte, S. Dutta, M.M. Berrey, E. Delpit,
D.M. Koelle, A. Sette, L. Corey and M.J. McElrath, Role for
HLA class II molecules in HIV-1 suppression and cellular
immunity following antiretroviral treatment, J Clin Invest
107 (2001), 505–517.
[46] A. Vyakarnam, D. Sidebottom, S. Murad, J.A. Underhill, P.J.
Easterbrook, A.G. Dalgleish and M. Peakman, Possession of
human leucocyte antigen DQ6 alleles and the rate of CD4
T-cell decline in human immunodeficiency virus-1 infection,
Immunology 112 (2004), 136–142.
[47] H. Hendel, S. Caillat-Zucman, H. Lebuanec, M. Carrington,
S. O’Brien, J.M. Andrieu, F. Schachter, D. Zagury, J. Rappa-
port, C. Winkler, G.W. Nelson and J.F. Zagury, New class I
and II HLA alleles strongly associated with opposite patterns
of progression to AIDS, J Immunol 162 (1999), 6942–6946.
[48] O. Lambotte, F. Boufassa, Y. Madec, A. Nguyen, C. Goujard,
L. Meyer, C. Rouzioux, A. Venet and J.F. Delfraissy, HIV
controllers: a homogeneous group of HIV-1-infected patients
with spontaneous control of viral replication, Clin Infect Dis
41 (2005), 1053–1056.
[49] S.J. O’Brien, X. Gao and M. Carrington, HLA and AIDS: a
cautionary tale, Trends Mol Med 7 (2001), 379–381.
[50] P. Kiepiela, K. Ngumbela, C. Thobakgale, D. Ramduth, I.
Honeyborne, E. Moodley, S. Reddy, C. de Pierres, Z. Mn-
cube, N. Mkhwanazi, K. Bishop, M. van der Stok, K. Nair,
N. Khan, H. Crawford, R. Payne, A. Leslie, J. Prado, A.
Prendergast, J. Frater, N. McCarthy, C. Brander, G.H. Learn,
D. Nickle, C. Rousseau, H. Coovadia, J.I. Mullins, D. Heck-
erman, B.D. Walker and P. Goulder, CD8+ T-cell responses
to different HIV proteins have discordant associations with
viral load, Nat Med 13 (2007), 46–53.
[51] M. Carrington and S.J. O’Brien, The influence of HLA geno-
type on AIDS, Annu Rev Med 54 (2003), 535–551.
[52] P.J. Goulder, M. Bunce, P. Krausa, K. McIntyre, S. Crowley,
B. Morgan, A. Edwards, P. Giangrande, R.E. Phillips and
A.J. McMichael, 1996. Novel, cross-restricted, conserved,
and immunodominant cytotoxic T lymphocyte epitopes in
slow progressors in HIV type 1 infection, AIDS Res Hum
Retroviruses 12 (2003), 1691–1698.
[53] S.A. Migueles, M.S. Sabbaghian, W.L. Shupert, M.P. Bet-
tinotti, F.M. Marincola, L. Martino, C.W. Hallahan, S.M.
Selig, D. Schwartz, J. Sullivan and M. Connors, HLA B*5701
is highly associated with restriction of virus replication in
a subgroup of HIV-infected long term nonprogressors, Proc
Natl Acad Sci U S A 97 (2000), 2709–2714.
[54] T. Miura, M.A. Brockman, A. Schneidewind, M. Lobritz, F.
Pereyra, A. Rathod, B.L. Block, Z.L. Brumme, C.J. Brumme,
B. Baker, A.C. Rothchild, B. Li, A. Trocha, E. Cutrell, N.
Frahm, C. Brander, I. Toth, E.J. Arts, T.M. Allen and B.D.
Walker, 2008. Hla-B57/B*5801 Hiv-1 Elite Controllers Se-
lect for Rare Gag Variants Associated with Reduced Viral
Replication Capacity and Strong Ctl Recognition, J Virol
(2000).
[55] J.G. Prado, I. Honeyborne, I. Brierley, M.C. Puertas, J.
Martinez-Picado and P.J. Goulder, Functional consequences
of human immunodeficiency virus escape from an HLA-
B*13-restricted CD8+ T-cell epitope in p1 Gag protein, J
Virol 83 (2009), 1018–1025.
[56] P.J. Goulder, R.E. Phillips, R.A. Colbert, S. McAdam, G.
Ogg, M.A. Nowak, P. Giangrande, G. Luzzi, B. Morgan,
A. Edwards, A.J. McMichael and S. Rowland-Jones, Late
escape from an immunodominant cytotoxic T-lymphocyte
response associated with progression to AIDS, Nat Med 3
(1997), 212–217.
[57] A.D. Kelleher, C. Long, E.C. Holmes, R.L. Allen, J. Wilson,
C. Conlon, C. Workman, S. Shaunak, K. Olson, P. Goulder,
C. Brander, G. Ogg, J.S. Sullivan, W. Dyer, I. Jones, A.J.
McMichael, S. Rowland-Jones and R.E. Phillips, Clustered
mutations in HIV-1 gag are consistently required for escape
from HLA-B27-restricted cytotoxic T lymphocyte responses,
B. Mothe et al. / Virological, immune and host genetics markers in the control of HIV infection 117
J Exp Med 193 (2001), 375–386.
[58] A. Schneidewind, M.A. Brockman, J. Sidney, Y.E. Wang, H.
Chen, T.J. Suscovich, B. Li, R.I. Adam, R.L. Allgaier, B.R.
Mothe, T. Kuntzen, C. Oniangue-Ndza, A. Trocha, X.G. Yu,
C. Brander, A. Sette, B.D. Walker and T.M. Allen, Struc-
tural and functional constraints limit options for cytotox-
ic T-lymphocyte escape in the immunodominant HLA-B27-
restricted epitope in human immunodeficiency virus type 1
capsid, J Virol 82 (2008), 5594–5605.
[59] Y.E. Wang, B. Li, J.M. Carlson, H. Streeck, A.D. Gladden,
R. Goodman, A. Schneidewind, K.A. Power, I. Toth, N.
Frahm, G. Alter, C. Brander, M. Carrington, B.D. Walker,
M. Altfeld, D. Heckerman and T.M. Allen, Protective HLA
class I alleles that restrict acute-phase CD8+ T-cell responses
are associated with viral escape mutations located in highly
conserved regions of human immunodeficiency virus type 1,
J Virol 83 (2009), 1845–1855.
[60] G. Alter, M.P. Martin, N. Teigen, W.H. Carr, T.J. Suscovich,
A. Schneidewind, H. Streeck, M. Waring, A. Meier, C. Bran-
der, J.D. Lifson, T.M. Allen, M. Carrington and M. Altfeld,
Differential natural killer cell-mediated inhibition of HIV-1
replication based on distinct KIR/HLA subtypes, J Exp Med
204 (2007), 3027–3036.
[61] M. Carrington, S. Wang, M.P. Martin, X. Gao, M. Schiff-
man, J. Cheng, R. Herrero, A.C. Rodriguez, R. Kurman, R.
Mortel, P. Schwartz, A. Glass and A. Hildesheim, Hierarchy
of resistance to cervical neoplasia mediated by combinations
of killer immunoglobulin-like receptor and human leukocyte
antigen loci, J Exp Med 201 (2005), 1069–1075.
[62] M.P. Martin, X. Gao, J.H. Lee, G.W. Nelson, R. Detels, J.J.
Goedert, S. Buchbinder, K. Hoots, D. Vlahov, J. Trowsdale,
M. Wilson, S.J. O’Brien and M. Carrington, Epistatic inter-
action between KIR3DS1 and HLA-B delays the progression
to AIDS, Nat Genet 31 (2002), 429–434.
[63] C.A. Muller, G. Engler-Blum, V. Gekeler, I. Steiert, E. Weiss
and H. Schmidt, Genetic and serological heterogeneity of
the supertypic HLA-B locus specificities Bw4 and Bw6, Im-
munogenetics 30 (1989), 200–207.
[64] P.O. Flores-Villanueva, E.J. Yunis, J.C. Delgado, E. Vit-
tinghoff, S. Buchbinder, J.Y. Leung, A.M. Uglialoro, O.P.
Clavijo, E.S. Rosenberg, S.A. Kalams, J.D. Braun, S.L.
Boswell, B.D. Walker and A.E. Goldfeld, Control of HIV-1
viremia and protection from AIDS are associated with HLA-
Bw4 homozygosity, Proc Natl Acad Sci U S A 98 (2001),
5140–5145.
[65] J.E. Gumperz, V. Litwin, J.H. Phillips, L.L. Lanier and P.
Parham, The Bw4 public epitope of HLA-B molecules con-
fers reactivity with natural killer cell clones that express
NKB1, a putative HLA receptor, J Exp Med 181 (1995),
1133–1144.
[66] M.P. Martin, Y. Qi, X. Gao, E. Yamada, J.N. Martin, F.
Pereyra, S. Colombo, E.E. Brown, W.L. Shupert, J. Phair, J.J.
Goedert, S. Buchbinder, G.D. Kirk, A. Telenti, M. Connors,
S.J. O’Brien, B.D. Walker, P. Parham, S.G. Deeks, D.W.
McVicar and M. Carrington, Innate partnership of HLA-B
and KIR3DL1 subtypes against HIV-1, Nat Genet 39 (2007),
733–740.
[67] B.J. Doranz, J. Rucker, Y. Yi, R.J. Smyth, M. Samson, S.C.
Peiper, M. Parmentier, R.G. Collman and R.W. Doms, A
dual-tropic primary HIV-1 isolate that uses fusin and the beta-
chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion
cofactors, Cell 85 (1996), 1149–1158.
[68] Y. Feng, C.C. Broder, P.E. Kennedy and E.A. Berger, HIV-
1 entry cofactor: functional cDNA cloning of a seven-
transmembrane, G protein-coupled receptor, Science 272
(1996), 872–877.
[69] S.A. Luther and J.G. Cyster, Chemokines as regulators of T
cell differentiation, Nat Immunol 2 (2001), 102–107.
[70] B. Moser and P. Loetscher, Lymphocyte traffic control by
chemokines, Nat Immunol 2 (2001), 123–128.
[71] M. Baggiolini, B. Dewald and B. Moser, Human chemokines:
an update, Annu Rev Immunol 15 (1997), 675–705.
[72] E.A. Berger, R.W. Doms, E.M. Fenyo, B.T. Korber, D.R.
Littman, J.P. Moore, Q.J. Sattentau, H. Schuitemaker, J. So-
droski and R.A. Weiss, A new classification for HIV-1, Na-
ture 391 (1998), 240.
[73] C.C. Bleul, M. Farzan, H. Choe, C. Parolin, I. Clark-Lewis, J.
Sodroski and T.A. Springer, The lymphocyte chemoattractant
SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry,
Nature 382 (1996), 829–833.
[74] F. Cocchi, A.L. DeVico, A. Garzino-Demo, S.K. Arya, R.C.
Gallo and P. Lusso, Identification of RANTES, MIP-1 al-
pha, and MIP-1 beta as the major HIV-suppressive factors
produced by CD8+ T cells, Science 270 (1995), 1811–1815.
[75] R. Horuk, Chemokine receptors and HIV-1: the fusion of
two major research fields, Immunol Today 20 (1999), 89–94.
[76] O.J. Cohen, M. Vaccarezza, G.K. Lam, B.F. Baird, K. Wildt,
P.M. Murphy, P.A. Zimmerman, T.B. Nutman, C.H. Fox, S.
Hoover, J. Adelsberger, M. Baseler, J. Arthos, R.T. Dav-
ey, Jr., R.L. Dewar, J. Metcalf, D.J. Schwartzentruber, J.M.
Orenstein, S. Buchbinder, A.J. Saah, R. Detels, J. Phair, C.
Rinaldo, J.B. Margolick, G. Pantaleo and A.S. Fauci, Het-
erozygosity for a defective gene for CC chemokine receptor
5 is not the sole determinant for the immunologic and viro-
logic phenotype of HIV-infected long-term nonprogressors,
J Clin Invest 100 (1997), 1581–1589.
[77] M. Dean, M. Carrington, C. Winkler, G.A. Huttley, M.W.
Smith, R. Allikmets, J.J. Goedert, S.P. Buchbinder, E. Vit-
tinghoff, E. Gomperts, S. Donfield, D. Vlahov, R. Kaslow,
A. Saah, C. Rinaldo, R. Detels and S.J. O’Brien, Genetic
restriction of HIV-1 infection and progression to AIDS by
a deletion allele of the CKR5 structural gene. Hemophilia
Growth and Development Study, Multicenter AIDS Cohort
Study, Multicenter Hemophilia Cohort Study, San Francisco
City Cohort, ALIVE Study, Science 273 (1996), 1856–1862.
[78] R. Liu, W.A. Paxton, S. Choe, D. Ceradini, S.R. Martin, R.
Horuk, M.E. MacDonald, H. Stuhlmann, R.A. Koup and N.R.
Landau, Homozygous defect in HIV-1 coreceptor accounts
for resistance of some multiply-exposed individuals to HIV-1
infection, Cell 86 (1996), 367–377.
[79] J. Rappaport, Y.Y. Cho, H. Hendel, E.J. Schwartz, F.
Schachter and J.F. Zagury, 32 bp CCR-5 gene deletion and re-
sistance to fast progression in HIV-1 infected heterozygotes,
Lancet 349 (1997), 922–923.
[80] D.H. McDermott, P.A. Zimmerman, F. Guignard, C.A. Klee-
berger, S.F. Leitman and P.M. Murphy, CCR5 promoter poly-
morphism and HIV-1 disease progression. Multicenter AIDS
Cohort Study (MACS), Lancet 352 (1998), 866–870.
[81] N.L. Michael, L.G. Louie, A.L. Rohrbaugh, K.A. Schultz,
D.E. Dayhoff, C.E. Wang and H.W. Sheppard, The role of
CCR5 and CCR2 polymorphisms in HIV-1 transmission and
disease progression, Nat Med 3 (1997), 1160–1162.
[82] L.G. Kostrikis, Y. Huang, J.P. Moore, S.M. Wolinsky, L.
Zhang, Y. Guo, L. Deutsch, J. Phair, A.U. Neumann and
D.D. Ho, A chemokine receptor CCR2 allele delays HIV-1
disease progression and is associated with a CCR5 promoter
mutation, Nat Med 4 (1998), 350–353.
[83] M.W. Smith, M. Dean, M. Carrington, C. Winkler, G.A. Hutt-
118 B. Mothe et al. / Virological, immune and host genetics markers in the control of HIV infection
ley, D.A. Lomb, J.J. Goedert, T.R. O’Brien, L.P. Jacobson, R.
Kaslow, S. Buchbinder, E. Vittinghoff, D. Vlahov, K. Hoots,
M.W. Hilgartner and S.J. O’Brien, Contrasting genetic influ-
ence of CCR2 and CCR5 variants on HIV-1 infection and
disease progression. Hemophilia Growth and Development
Study (HGDS), Multicenter AIDS Cohort Study (MACS),
Multicenter Hemophilia Cohort Study (MHCS), San Francis-
co City Cohort (SFCC), ALIVE Study, Science 277 (1997),
959–965.
[84] S.A. Mulherin, T.R. O’Brien, J.P. Ioannidis, J.J. Goedert, S.P.
Buchbinder, R.A. Coutinho, B.D. Jamieson, L. Meyer, N.L.
Michael, G. Pantaleo, G.P. Rizzardi, H. Schuitemaker, H.W.
Sheppard, I.D. Theodorou, D. Vlahov and P.S. Rosenberg,
Effects of CCR5-Delta32 and CCR2-64I alleles on HIV-1
disease progression: the protection varies with duration of
infection, AIDS 17 (2003), 377–387.
[85] R.M. Gulick, J. Lalezari, J. Goodrich, N. Clumeck, E. De-
Jesus, A. Horban, J. Nadler, B. Clotet, A. Karlsson, M.
Wohlfeiler, J.B. Montana, M. McHale, J. Sullivan, C. Ridg-
way, S. Felstead, M.W. Dunne, E. van der Ryst and H. May-
er, Maraviroc for previously treated patients with R5 HIV-1
infection, N Engl J Med 359 (2008), 1429–1441.
[86] R.J. Landovitz, J.B. Angel, C. Hoffmann, H. Horst, M.
Opravil, J. Long, W. Greaves and G. Fatkenheuer, Phase
II study of vicriviroc versus efavirenz (both with zidovu-
dine/lamivudine) in treatment-naive subjects with HIV-1 in-
fection, J Infect Dis 198 (2008), 1113–1122.
[87] G. Hutter, D. Nowak, M. Mossner, S. Ganepola, A. Mussig,
K. Allers, T. Schneider, J. Hofmann, C. Kucherer, O. Blau,
I.W. Blau, W.K. Hofmann and E. Thiel, Long-term control
of HIV by CCR5 Delta32/Delta32 stem-cell transplantation,
N Engl J Med 360 (2009), 692–698.
[88] C.A. Derdeyn, C. Costello, J.M. Kilby, G. Sfakianos, M.S.
Saag, R. Kaslow and R.P. Bucy, Correlation between circulat-
ing stromal cell-derived factor 1 levels and CD4+ cell count
in human immunodeficiency virus type 1-infected individu-
als, AIDS Res Hum Retroviruses 15 (1999), 1063–1071.
[89] H. Liu, D. Chao, E.E. Nakayama, H. Taguchi, M. Goto, X.
Xin, J.K. Takamatsu, H. Saito, Y. Ishikawa, T. Akaza, T.
Juji, Y. Takebe, T. Ohishi, K. Fukutake, Y. Maruyama, S.
Yashiki, S. Sonoda, T. Nakamura, Y. Nagai, A. Iwamoto and
T. Shioda, Polymorphism in RANTES chemokine promoter
affects HIV-1 disease progression, Proc Natl Acad Sci U S A
96 (1999), 4581–4585.
[90] D.H. McDermott, M.J. Beecroft, C.A. Kleeberger, F.M. Al-
Sharif, W.E. Ollier, P.A. Zimmerman, B.A. Boatin, S.F. Leit-
man, R. Detels, A.H. Hajeer and P.M. Murphy, Chemokine
RANTES promoter polymorphism affects risk of both HIV
infection and disease progression in the Multicenter AIDS
Cohort Study, AIDS 14 (2000), 2671–2678.
[91] A. Brambilla, C. Villa, G. Rizzardi, F. Veglia, S. Ghezzi,
A. Lazzarin, M. Cusini, S. Muratori, E. Santagostino, A.
Gringeri, L.G. Louie, H.W. Sheppard, G. Poli, N.L. Michael,
G. Pantaleo and E. Vicenzi, Shorter survival of SDF1-
3’A/3’A homozygotes linked to CD4+ T cell decrease in
advanced human immunodeficiency virus type 1 infection, J
Infect Dis 182 (2000), 311–315.
[92] O. Chaudhary, K. Rajsekar, I. Ahmed, R. Verma, M. Bala,
R. Bhasin and K. Luthra, Polymorphic variants in DC-SIGN,
DC-SIGNR and SDF-1 in high risk seronegative and HIV-1
patients in Northern Asian Indians, J Clin Virol 43 (2008),
196–201.
[93] H. Liu, Y. Hwangbo, S. Holte, J. Lee, C. Wang, N. Kaupp,
H. Zhu, C. Celum, L. Corey, M.J. McElrath and T. Zhu,
Analysis of genetic polymorphisms in CCR5, CCR2, stromal
cell-derived factor-1, RANTES, and dendritic cell-specific
intercellular adhesion molecule-3-grabbing nonintegrin in
seronegative individuals repeatedly exposed to HIV-1, J In-
fect Dis 190 (2004), 1055–1058.
[94] C. Winkler, W. Modi, M.W. Smith, G.W. Nelson, X. Wu, M.
Carrington, M. Dean, T. Honjo, K. Tashiro, D. Yabe, S. Buch-
binder, E. Vittinghoff, J.J. Goedert, T.R. O’Brien, L.P. Ja-
cobson, R. Detels, S. Donfield, A. Willoughby, E. Gomperts,
D. Vlahov, J. Phair and S.J. O’Brien, Genetic restriction of
AIDS pathogenesis by an SDF-1 chemokine gene variant.
ALIVE Study, Hemophilia Growth and Development Study
(HGDS), Multicenter AIDS Cohort Study (MACS), Mul-
ticenter Hemophilia Cohort Study (MHCS), San Francisco
City Cohort (SFCC), Science 279 (1998), 389–393.
[95] T. Nagasawa, Role of chemokine SDF-1/PBSF and its recep-
tor CXCR4 in blood vessel development, Ann N Y Acad Sci
947 (2001), 112–115; discussion 115–116.
[96] E. Gonzalez, H. Kulkarni, H. Bolivar, A. Mangano, R.
Sanchez, G. Catano, R.J. Nibbs, B.I. Freedman, M.P.
Quinones, M.J. Bamshad, K.K. Murthy, B.H. Rovin, W.
Bradley, R.A. Clark, S.A. Anderson, J. O’Connell R, B.K.
Agan, S.S. Ahuja, R. Bologna, L. Sen, M.J. Dolan and S.K.
Ahuja, The influence of CCL3L1 gene-containing segmen-
tal duplications on HIV-1/AIDS susceptibility, Science 307
(2005), 1434–1440.
[97] M.P. Martin, M.M. Lederman, H.B. Hutcheson, J.J. Goedert,
G.W. Nelson, Y. van Kooyk, R. Detels, S. Buchbinder, K.
Hoots, D. Vlahov, S.J. O’Brien and M. Carrington, Associ-
ation of DC-SIGN promoter polymorphism with increased
risk for parenteral, but not mucosal, acquisition of human
immunodeficiency virus type 1 infection, J Virol 78 (2004),
14053–14056.
[98] P. Selvaraj, K. Alagarasu, S. Swaminathan, M. Harishankar
and G. Narendran, CD209 gene polymorphisms in South
Indian HIV and HIV-TB patients, Infect Genet Evol 9 (2009),
256–262.
[99] R.A. Koup and D.D. Ho, Shutting down HIV, Nature 370
(1994), 416.
[100] G. Pantaleo, J.F. Demarest, T. Schacker, M. Vaccarezza,
O.J. Cohen, M. Daucher, C. Graziosi, S.S. Schnittman, T.C.
Quinn, G.M. Shaw, L. Perrin, G. Tambussi, A. Lazzarin, R.P.
Sekaly, H. Soudeyns, L. Corey and A.S. Fauci, The qualita-
tive nature of the primary immune response to HIV infection
is a prognosticator of disease progression independent of the
initial level of plasma viremia, Proc Natl Acad Sci U S A 94
(1997), 254–258.
[101] T.C. Friedrich, L.E. Valentine, L.J. Yant, E.G. Rakasz, S.M.
Piaskowski, J.R. Furlott, K.L. Weisgrau, B. Burwitz, G.E.
May, E.J. Leon, T. Soma, G. Napoe, S.V. Capuano, 3rd,
N.A. Wilson and D.I. Watkins, Subdominant CD8+ T-cell
responses are involved in durable control of AIDS virus repli-
cation, J Virol 81 (2007), 3465–3476.
[102] J.E. Schmitz, M.J. Kuroda, S. Santra, V.G. Sasseville, M.A.
Simon, M.A. Lifton, P. Racz, K. Tenner-Racz, M. Dalesan-
dro, B.J. Scallon, J. Ghrayeb, M.A. Forman, D.C. Monte-
fiori, E.P. Rieber, N.L. Letvin and K.A. Reimann, Control
of viremia in simian immunodeficiency virus infection by
CD8+ lymphocytes, Science 283 (1999), 857–860.
[103] J.D. Altman, P.A. Moss, P.J. Goulder, D.H. Barouch, M.G.
McHeyzer-Williams, J.I. Bell, A.J. McMichael and M.M.
Davis, Phenotypic analysis of antigen-specific T lympho-
cytes, Science 274 (1996), 94–96.
[104] P.J. Goulder, Y. Tang, C. Brander, M.R. Betts, M. Altfeld, K.
B. Mothe et al. / Virological, immune and host genetics markers in the control of HIV infection 119
Annamalai, A. Trocha, S. He, E.S. Rosenberg, G. Ogg, C.A.
O’Callaghan, S.A. Kalams, R.E. McKinney, Jr., K. Mayer,
R.A. Koup, S.I. Pelton, S.K. Burchett, K. McIntosh and B.D.
Walker, Functionally inert HIV-specific cytotoxic T lympho-
cytes do not play a major role in chronically infected adults
and children, J Exp Med 192 (2000), 1819–1832.
[105] G.S. Ogg, X. Jin, S. Bonhoeffer, P.R. Dunbar, M.A. Nowak,
S. Monard, J.P. Segal, Y. Cao, S.L. Rowland-Jones, V. Cerun-
dolo, A. Hurley, M. Markowitz, D.D. Ho, D.F. Nixon and
A.J. McMichael, Quantitation of HIV-1-specific cytotoxic
T lymphocytes and plasma load of viral RNA, Science 279
(1998), 2103–2106.
[106] C. Brander, K.E. Hartman, A.K. Trocha, N.G. Jones, R.P.
Johnson, B. Korber, P. Wentworth, S.P. Buchbinder, S. Wolin-
sky, B.D. Walker and S.A. Kalams, Lack of strong immune
selection pressure by the immunodominant, HLA-A*0201-
restricted cytotoxic T lymphocyte response in chronic hu-
man immunodeficiency virus-1 infection, J Clin Invest 101
(1998), 2559–2566.
[107] O.O. Yang, S.A. Kalams, M. Rosenzweig, A. Trocha, N.
Jones, M. Koziel, B.D. Walker and R.P. Johnson, Efficient
lysis of human immunodeficiency virus type 1-infected cells
by cytotoxic T lymphocytes, J Virol 70 (1996), 5799–5806.
[108] O.O. Yang, S.A. Kalams, A. Trocha, H. Cao, A. Luster, R.P.
Johnson and B.D. Walker, Suppression of human immunod-
eficiency virus type 1 replication by CD8+ cells: evidence
for HLA class I-restricted triggering of cytolytic and noncy-
tolytic mechanisms, J Virol 71 (1997), 3120–3128.
[109] N. Frahm, B.T. Korber, C.M. Adams, J.J. Szinger, R. Draen-
ert, M.M. Addo, M.E. Feeney, K. Yusim, K. Sango, N.V.
Brown, D. SenGupta, A. Piechocka-Trocha, T. Simonis, F.M.
Marincola, A.G. Wurcel, D.R. Stone, C.J. Russell, P. Adolf,
D. Cohen, T. Roach, A. StJohn, A. Khatri, K. Davis, J.
Mullins, P.J. Goulder, B.D. Walker and C. Brander, Consis-
tent cytotoxic-T-lymphocyte targeting of immunodominant
regions in human immunodeficiency virus across multiple
ethnicities, J Virol 78 (2004), 2187–2200.
[110] A. Saez-Cirion, C. Lacabaratz, O. Lambotte, P. Versmisse,
A. Urrutia, F. Boufassa, F. Barre-Sinoussi, J.F. Delfraissy,
M. Sinet, G. Pancino and A. Venet, HIV controllers exhibit
potent CD8 T cell capacity to suppress HIV infection ex vivo
and peculiar cytotoxic T lymphocyte activation phenotype,
Proc Natl Acad Sci U S A 104 (2007), 6776–6781.
[111] C. Brander, N. Frahm and B.D. Walker, 2006. The challenges
of host and viral diversity in HIV vaccine design, Curr Opin
Immunol 18 (2007), 430–437.
[112] R. Zuniga, A. Lucchetti, P. Galvan, S. Sanchez, C. Sanchez,
A. Hernandez, H. Sanchez, N. Frahm, C.H. Linde, H.S. He-
witt, W. Hildebrand, M. Altfeld, T.M. Allen, B.D. Walker,
B.T. Korber, T. Leitner, J. Sanchez and C. Brander, Relative
dominance of Gag p24-specific cytotoxic T lymphocytes is
associated with human immunodeficiency virus control, J
Virol 80 (2006), 3122–3125.
[113] M. Altfeld, E.T. Kalife, Y. Qi, H. Streeck, M. Lichterfeld,
M.N. Johnston, N. Burgett, M.E. Swartz, A. Yang, G. Alter,
X.G. Yu, A. Meier, J.K. Rockstroh, T.M. Allen, H. Jessen,
E.S. Rosenberg, M. Carrington and B.D. Walker, HLA Alle-
les Associated with Delayed Progression to AIDS Contribute
Strongly to the Initial CD8(+) T Cell Response against HIV-
1, PLoS Med 3 (2006), e403.
[114] B.H. Edwards, A. Bansal, S. Sabbaj, J. Bakari, M.J. Mulligan
and P.A. Goepfert, Magnitude of functional CD8+ T-cell
responses to the gag protein of human immunodeficiency
virus type 1 correlates inversely with viral load in plasma, J
Virol 76 (2002), 2298–2305.
[115] I. Honeyborne, A. Prendergast, F. Pereyra, A. Leslie, H.
Crawford, R. Payne, S. Reddy, K. Bishop, E. Moodley, K.
Nair, M. van der Stok, N. McCarthy, C.M. Rousseau, M.
Addo, J.I. Mullins, C. Brander, P. Kiepiela, B.D. Walker and
P.J. Goulder, Control of human immunodeficiency virus type
1 is associated with HLA-B*13 and targeting of multiple
gag-specific CD8+ T-cell epitopes, J Virol 81 (2007), 3667–
3672.
[116] A. Masemola, T. Mashishi, G. Khoury, P. Mohube, P. Mok-
gotho, E. Vardas, M. Colvin, L. Zijenah, D. Katzenstein,
R. Musonda, S. Allen, N. Kumwenda, T. Taha, G. Gray, J.
McIntyre, S.A. Karim, H.W. Sheppard and C.M. Gray, Hi-
erarchical targeting of subtype C human immunodeficiency
virus type 1 proteins by CD8+ T cells: correlation with viral
load, J Virol 78 (2004), 3233–3243.
[117] M.L. Ndongala, Y. Peretz, S. Boulet, M. Doroudchi, B.
Yassine-Diab, M.R. Boulassel, D. Rouleau, C. Tremblay, R.
Leblanc, J.P. Routy, R.P. Sekaly and N.F. Bernard, HIV Gag
p24 specific responses secreting IFN-gamma and/or IL-2 in
treatment-naive individuals in acute infection early disease
(AIED) are associated with low viral load, Clin Immunol
(2009).
[118] J.B. Sacha, C. Chung, E.G. Rakasz, S.P. Spencer, A.K. Jonas,
A.T. Bean, W. Lee, B.J. Burwitz, J.J. Stephany, J.T. Lof-
fredo, D.B. Allison, S. Adnan, A. Hoji, N.A. Wilson, T.C.
Friedrich, J.D. Lifson, O.O. Yang and D.I. Watkins, Gag-
specific CD8+ T lymphocytes recognize infected cells be-
fore AIDS-virus integration and viral protein expression, J
Immunol 178 (2007), 2746–2754.
[119] M.R. Betts, M.C. Nason, S.M. West, S.C. De Rosa, S.A.
Migueles, J. Abraham, M.M. Lederman, J.M. Benito, P.A.
Goepfert, M. Connors, M. Roederer and R.A. Koup, HIV
nonprogressors preferentially maintain highly functional
HIV-specific CD8+ T cells, Blood 107 (2006), 4781–4789.
[120] S.A. Migueles, A.C. Laborico, W.L. Shupert, M.S. Sabbaghi-
an, R. Rabin, C.W. Hallahan, D. Van Baarle, S. Kostense, F.
Miedema, M. McLaughlin, L. Ehler, J. Metcalf, S. Liu and M.
Connors, HIV-specific CD8+ T cell proliferation is coupled
to perforin expression and is maintained in nonprogressors,
Nat Immunol 3 (2002), 1061–1068.
[121] D. Yerly, D. Heckerman, T. Allen, T.J. Suscovich, N. Jojic,
C. Kadie, W.J. Pichler, A. Cerny and C. Brander, Design,
expression, and processing of epitomized hepatitis C virus-
encoded CTL epitopes, J Immunol 181 (2008), 6361–6370.
[122] D. Yerly, D. Heckerman, T.M. Allen, J.V. Chisholm, 3rd,
K. Faircloth, C.H. Linde, N. Frahm, J. Timm, W.J. Pichler,
A. Cerny and C. Brander, Increased cytotoxic T-lymphocyte
epitope variant cross-recognition and functional avidity are
associated with hepatitis C virus clearance, J Virol 82 (2008),
3147–3153.
[123] T.M. Allen, M. Altfeld, S.C. Geer, E.T. Kalife, C. Moore,
M. O’Sullivan K, I. Desouza, M.E. Feeney, R.L. Eldridge,
E.L. Maier, D.E. Kaufmann, M.P. Lahaie, L. Reyor, G. Tanzi,
M.N. Johnston, C. Brander, R. Draenert, J.K. Rockstroh,
H. Jessen, E.S. Rosenberg, S.A. Mallal and B.D. Walker,
Selective escape from CD8+ T-cell responses represents a
major driving force of human immunodeficiency virus type 1
(HIV-1) sequence diversity and reveals constraints on HIV-1
evolution, J Virol 79 (2005), 13239–13249.
[124] T.M. Allen, M. Altfeld, X.G. Yu, K.M. O’Sullivan, M.
Lichterfeld, S. Le Gall, M. John, B.R. Mothe, P.K. Lee, E.T.
Kalife, D.E. Cohen, K.A. Freedberg, D.A. Strick, M.N. John-
ston, A. Sette, E.S. Rosenberg, S.A. Mallal, P.J. Goulder, C.
120 B. Mothe et al. / Virological, immune and host genetics markers in the control of HIV infection
Brander and B.D. Walker, Selection, transmission, and rever-
sion of an antigen-processing cytotoxic T-lymphocyte escape
mutation in human immunodeficiency virus type 1 infection,
J Virol 78 (2004), 7069–7078.
[125] R. Draenert, S. Le Gall, K.J. Pfafferott, A.J. Leslie, P. Chetty,
C. Brander, E.C. Holmes, S.C. Chang, M.E. Feeney, M.M.
Addo, L. Ruiz, D. Ramduth, P. Jeena, M. Altfeld, S. Thomas,
Y. Tang, C.L. Verrill, C. Dixon, J.G. Prado, P. Kiepiela,
J. Martinez-Picado, B.D. Walker and P.J. Goulder, Immune
selection for altered antigen processing leads to cytotoxic T
lymphocyte escape in chronic HIV-1 infection, J Exp Med
199 (2004), 905–915.
[126] A.J. Leslie, K.J. Pfafferott, P. Chetty, R. Draenert, M.M. Ad-
do, M. Feeney, Y. Tang, E.C. Holmes, T. Allen, J.G. Prado,
M. Altfeld, C. Brander, C. Dixon, D. Ramduth, P. Jeena, S.A.
Thomas, A. St John, T.A. Roach, B. Kupfer, G. Luzzi, A.
Edwards, G. Taylor, H. Lyall, G. Tudor-Williams, V. Novelli,
J. Martinez-Picado, P. Kiepiela, B.D. Walker and P.J. Goul-
der, HIV evolution: CTL escape mutation and reversion after
transmission, Nat Med 10 (2004), 282–289.
[127] J. Martinez-Picado, J.G. Prado, E.E. Fry, K. Pfafferott, A.
Leslie, S. Chetty, C. Thobakgale, I. Honeyborne, H. Craw-
ford, P. Matthews, T. Pillay, C. Rousseau, J.I. Mullins, C.
Brander, B.D. Walker, D.I. Stuart, P. Kiepiela and P. Goulder,
Fitness cost of escape mutations in p24 Gag in association
with control of human immunodeficiency virus type 1, J Virol
80 (2006), 3617–3623.
[128] F.W. Peyerl, H.S. Bazick, M.H. Newberg, D.H. Barouch, J.
Sodroski and N.L. Letvin, Fitness costs limit viral escape
from cytotoxic T lymphocytes at a structurally constrained
epitope, J Virol 78 (2004), 13901–13910.
[129] Z.L. Brumme, C.J. Brumme, D. Heckerman, B.T. Korber,
M. Daniels, J. Carlson, C. Kadie, T. Bhattacharya, C. Chui,
J. Szinger, T. Mo, R.S. Hogg, J.S. Montaner, N. Frahm, C.
Brander, B.D. Walker and P.R. Harrigan, Evidence of differ-
ential HLA class I-mediated viral evolution in functional and
accessory/regulatory genes of HIV-1, PLoS Pathog 3 (2007),
e94.
[130] Z.L. Brumme, I. Tao, S. Szeto, C.J. Brumme, J.M. Carlson,
D. Chan, C. Kadie, N. Frahm, C. Brander, B. Walker, D.
Heckerman and P.R. Harrigan, Human leukocyte antigen-
specific polymorphisms in HIV-1 Gag and their associa-
tion with viral load in chronic untreated infection, AIDS 22
(2008), 1277–1286.
[131] S.A. Kalams, S.P. Buchbinder, E.S. Rosenberg, J.M. Billings-
ley, D.S. Colbert, N.G. Jones, A.K. Shea, A.K. Trocha and
B.D. Walker, Association between virus-specific cytotoxic
T-lymphocyte and helper responses in human immunodefi-
ciency virus type 1 infection, J Virol 73 (1999), 6715–6720.
[132] S.A. Kalams, P.J. Goulder, A.K. Shea, N.G. Jones, A.K.
Trocha, G.S. Ogg and B.D. Walker, Levels of human immun-
odeficiency virus type 1-specific cytotoxic T-lymphocyte ef-
fector and memory responses decline after suppression of
viremia with highly active antiretroviral therapy, J Virol 73
(1999), 6721–6728.
[133] M. Lichterfeld, D.E. Kaufmann, X.G. Yu, S.K. Mui, M.M.
Addo, M.N. Johnston, D. Cohen, G.K. Robbins, E. Pae, G.
Alter, A. Wurcel, D. Stone, E.S. Rosenberg, B.D. Walker and
M. Altfeld, Loss of HIV-1-specific CD8+ T cell prolifera-
tion after acute HIV-1 infection and restoration by vaccine-
induced HIV-1-specific CD4+ T cells, J Exp Med 200 (2004),
701–712.
[134] O. Gasser, F.K. Bihl, M. Wolbers, E. Loggi, I. Steffen, H.H.
Hirsch, H.F. Gunthard, B.D. Walker, C. Brander, M. Bat-
tegay and C. Hess, 2007. HIV patients developing primary
CNS lymphoma lack EBV-specific CD4+ T cell function
irrespective of absolute CD4+ T cell counts, PLoS Med 4
(2004), e96.
[135] O. Gasser, B.F., S. Sanghavi, C. Rinaldo, D. Rowe, C. Hess,
D. Stablein, M. Roland, P. Stock and C. Brander, Treatment-
dependent loss of polyfunctional CD8+ T-cell responses in
HIV-infected kidney transplant recipients is associated with
herpesvirus reactivation, American Journal of Transplanta-
tion (2009), in press.
[136] V. Martinez, D. Costagliola, O. Bonduelle, N. N’go, A.
Schnuriger, I. Theodorou, J.P. Clauvel, D. Sicard, H. Agut,
P. Debre, C. Rouzioux and B. Autran, Combination of HIV-
1-specific CD4 Th1 cell responses and IgG2 antibodies is the
best predictor for persistence of long-term nonprogression, J
Infect Dis 191 (2005), 2053–2063.
[137] N. Ngo-Giang-Huong, D. Candotti, A. Goubar, B. Autran,
M. Maynart, D. Sicard, J.P. Clauvel, H. Agut, D. Costagli-
ola and C. Rouzioux, 2001. HIV type 1-specific IgG2 anti-
bodies: markers of helper T cell type 1 response and prog-
nostic marker of long-term nonprogression, AIDS Res Hum
Retroviruses 17 (2005), 1435–1446.
[138] A. Trkola, H. Kuster, P. Rusert, B. Joos, M. Fischer, C. Lee-
mann, A. Manrique, M. Huber, M. Rehr, A. Oxenius, R.
Weber, G. Stiegler, B. Vcelar, H. Katinger, L. Aceto and
H.F. Gunthard, Delay of HIV-1 rebound after cessation of
antiretroviral therapy through passive transfer of human neu-
tralizing antibodies, Nat Med 11 (2005), 615–622.
[139] D.C. Montefiori, G. Pantaleo, L.M. Fink, J.T. Zhou, J.Y.
Zhou, M. Bilska, G.D. Miralles and A.S. Fauci, Neutralizing
and infection-enhancing antibody responses to human im-
munodeficiency virus type 1 in long-term nonprogressors, J
Infect Dis 173 (1996), 60–67.
[140] Q. Li, L. Duan, J.D. Estes, Z.M. Ma, T. Rourke, Y. Wang,
C. Reilly, J. Carlis, C.J. Miller and A.T. Haase, Peak SIV
replication in resting memory CD4+ T cells depletes gut
lamina propria CD4+ T cells, Nature 434 (2005), 1148–
1152.
[141] J.J. Mattapallil, D.C. Douek, B. Hill, Y. Nishimura, M. Mar-
tin and M. Roederer, Massive infection and loss of memory
CD4+ T cells in multiple tissues during acute SIV infection,
Nature 434 (2005), 1093–1097.
[142] S. Mehandru, M.A. Poles, K. Tenner-Racz, A. Horowitz, A.
Hurley, C. Hogan, D. Boden, P. Racz and M. Markowitz,
Primary HIV-1 infection is associated with preferential de-
pletion of CD4+ T lymphocytes from effector sites in the
gastrointestinal tract, J Exp Med 200 (2004), 761–770.
[143] J.M. Brenchley, D.A. Price and D.C. Douek, HIV disease:
fallout from a mucosal catastrophe? Nat Immunol 7 (2006),
235–239.
[144] C. Guarner and G. Soriano, Bacterial translocation and its
consequences in patients with cirrhosis, Eur J Gastroenterol
Hepatol 17 (2005), 27–31.
[145] M. Carrington, M.P. Martin and J. van Bergen, KIR-HLA
intercourse in HIV disease, Trends Microbiol 16 (2008), 620–
627.
[146] P.Y. Bochud, M. Bochud, A. Telenti and T. Calandra, Innate
immunogenetics: a tool for exploring new frontiers of host
defence, Lancet Infect Dis 7 (2007), 531–542.
[147] J.C. Sun, J.N. Beilke and L.L. Lanier, Adaptive immune
features of natural killer cells, Nature 457 (2009), 557–561.
